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1. Introduction 
Neuroblastoma is one of the most intensely studied solid malignancies that affect children 
(Maris & Matthay, 1999). These tumours are heterogeneous biologically and clinically. One 
subset of neuroblastoma is susceptible to spontaneous apoptosis with little or no therapy 
and another subset differentiates over time, but most of these tumours are difficult to cure 
with current treatments. A relatively high proportion of affected children die due to 
resistance of the neuroblastoma to therapy (Van Roy et al., 2009). Every step in the 
identification or functional understanding of the genes that play important roles in this 
cancer could bring us closer to understanding the molecular mechanism and could help to 
develop more effective therapy. 
We will describe the novel NBPF gene family and its role in neuroblastoma. The NBPF gene 
family was originally identified by the disruption of one of its members in a neuroblastoma 
patient (Vandepoele et al., 2008). This gene was named NBPF1, for Neuroblastoma 
Breakpoint Family, member 1. Several reports indicate that the NBPF gene family might 
play an important role in neuroblastoma and possibly in other cancers as well. Additionally, 
this evolutionarily recent gene family has been involved as an important player in human 
evolution. 
2. Identification of NBPF1 during the positional cloning of a constitutional 
translocation in a neuroblastoma patient 
In 1983, karyotypic analysis of fibroblasts from a Belgian neuroblastoma patient revealed a 
de novo, constitutional translocation between chromosomes 1p36.2 and 17q11.2 (Laureys et 
al., 1990; Laureys et al., 1995). These two chromosomal regions are often rearranged in 
sporadic neuroblastoma tumours (Savelyeva et al., 1994). So it was believed that the 
translocation had predisposed the patient to neuroblastoma by disrupting one or more 
genes. Although previous cytogenetic experiments indicated that the translocation was 
balanced, analysis of the breakpoint sequences showed greater complexity (Figure 1). First, 
in both derivative chromosomes, a few nucleotides of unknown origin were inserted 
between the chromosome 1 and 17 sequences (Vandepoele et al., 2008). Such insertions are 
frequently observed in reciprocal constitutional translocations (Willett-Brozick et al., 2001). 
Second, on chromosome 1, the translocation resulted in the deletion of a genomic fragment 
of 5,215 base pairs that is present in the human genome reference sequence (Vandepoele et 
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al., 2008). However, numerous reports describe structural variation at this locus (see below), 
which makes it impossible to determine the precise size of the deletion in this 
neuroblastoma patient. No deletions or insertions of genomic regions were observed on 
chromosome 17, which means that the translocation at this level is indeed balanced. 
Notably, both translocation breakpoints are located in LINE repeats, classified as type L1-
PA4 for chromosome 1 and as type L2 for chromosome 17, but no significant sequence 
homology between these two LINE repeats was found. Therefore, most probably these 
repeats do not participate in the mechanism of this translocation (Vandepoele et al., 2008). 
 
 
Fig. 1. Genomic overview of the translocation breakpoint of the der(1) and der(17) 
chromosomes.  
Central box: Normal 1p36 and 17q12 chromosomes. Both translocation breakpoints (BP) on 
chromosome 1 are located in intronic regions of the NBPF1 gene, and the translocation 
results in deletion of 5,215 bp. The translocation breakpoint on chromosome 17 is located in 
the ACCN1 gene and disrupts only isoform 2. Top: On the der(1) chromosome, the 
translocation gives rise to two chimeric transcripts of NBPF1 sequences (NBPF1-CHI) fused 
to sequences derived from chromosome 17 (grey box), thereby extending the open reading 
frame. Translocation of the promoter and the first exon of ACCN1 isoform 2 might result in 
chimeric transcripts on der(1), but so far no transcripts have been isolated (question mark 
with dotted line). Bottom: On the der(17) chromosome, isoform 2 of the ACCN1 gene is 
probably no longer expressed due to loss of its promoter and first exon (dotted line with 
question mark), whereas the last three NBPF1 exons are translocated to the der(17) 
chromosome (exon types 11, 12 and 14) (Modified after Vandepoele et al., 2008). 
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On chromosome 17, the translocation disrupts ACCN1, a potential glioma tumour 
suppressor gene (Vila-Carriles et al., 2006). ACCN1 encodes a member of the superfamily of 
amiloride-sensitive degenerin/epithelial sodium channels (DEG/ENaC) and is also known 
as MDEG (Waldmann et al., 1996), BNaC1 (Garcia-Anoveros et al., 1997) and ASIC2 
(Waldmann et al., 1997). ACCN1 is expressed primarily in the brain, where it might play a 
role in neurotransmission (Garcia-Anoveros et al., 1997). Alternative initiation of 
transcription results in two variants encoding distinct isoforms differing in their N-terminal 
domains (Lingueglia et al., 1997). The translocation in the neuroblastoma patient disrupts 
only isoform 2 of the ACCN1 gene. Translocation of the promoter and the first exon of 
ACCN1 isoform 2 could result in chimeric transcripts from the derivative chromosome 1 
(der(1)), but no such transcripts could be identified. Isoform 2 is probably not expressed 
from derivative chromosome 17 (der(17)) due to the loss of its promoter and first exon 
(Figure 1) (Vandepoele et al., 2008). 
Oncomine expression analysis (Rhodes et al., 2007) of ACCN1 showed that it is expressed at 
significantly lower levels in neuroblastoma tumours with MYCN amplification, in higher 
stage tumours, and in tumours with 1p36 loss of heterozygosity. These findings indicate that 
ACCN1 plays a role in tumour aggressiveness (Vandepoele et al., 2008). ACCN1 also has a 
role in oncogenesis of glioma cells, in which functional restoration of ACCN1 at the plasma 
membrane decreases cell migration (Vila-Carriles et al., 2006). Gain of chromosome 17q is 
the most frequent genetic alteration observed in neuroblastoma, but the biological basis is 
complex because dosage alterations involve genes localised on both sides of the 17q 
breakpoints. It has been suggested that genes mapping between 17cen and 17q12 suppress 
tumour progression, whereas genes mapping between 17q23.1 and 17qter promote its 
progression (Lastowska et al., 2002). These findings further stress the possible role of ACCN1 
as a tumour suppressor of neuroblastoma. 
Cloning of the chromosome 1 breakpoint identified a novel gene that is disrupted by this 
translocation. This gene was named NBPF1, for Neuroblastoma Breakpoint Family, member 
1. NBPF1 is a member of a newly discovered gene family with an intricate genomic structure 
(see section 3.1). The translocation truncates NBPF1 and gives rise to two chimeric 
transcripts of NBPF1 sequences fused to sequences derived from chromosome 17, thereby 
extending the open reading frame with either 34 or 11 additional codons. The breakpoint of 
the der(1) chromosome is located in an intron between exon types 7 and 8 (Figure 1). The 
translocation breakpoint of the der(17) chromosome is also intronic, but it is located between 
exon types 13 and 11, which results in deletion of a part of the NBPF1 gene, as described 
above. The three last NBPF1 exons, of type 11, 12 and 14, are translocated to the der(17) 
chromosome, but so far no chimeric transcripts have been described (Figure 1) (Vandepoele 
et al., 2008). 
We determined the expression level of NBPF1 in 32 neuroblastoma cell lines. This profiling 
showed that NBPF1 expression varied widely between the different samples, in line with a 
previous expression analysis of the total NBPF family (Vandepoele et al., 2008). Interestingly, 
we did not observe complete loss of NBPF1 expression in any cell line, as has been reported 
for other genes located in the 1p36 region (Janoueix-Lerosey et al., 2004; Fransson et al., 
2007). Statistical analysis of these data revealed a significantly lower expression level of 
NBPF1 in cell lines with a heterozygous deletion of the NBPF1 locus than in cell lines 
without NBPF1 loss (p<0.05), indicating that NBPF1 could be a tumour suppressor gene 
(TSG) in neuroblastoma. Although this decreased expression of NBPF1 might be explained 
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by the lower gene copy number, it is striking that such downregulation was observed for 
only 15–20% of the genes affected by hemizygosity of this region (Janoueix-Lerosey et al., 
2004). Therefore, in addition to loss of heterozygosity, other mechanisms probably play a 
role in downregulation of some of these genes. It has been proposed that the combined 
decrease in the expression of these genes, rather than the inactivation of one single classical 
TSG, could cause the unfavourable outcome associated with 1p deletions in neuroblastoma 
(Fransson et al., 2007). Oncomine analysis (Rhodes et al., 2007) showed that in two studies 
there was no significant difference in NBPF expression between different tumour grades or 
INSS stages but one study showed decreased NBPF levels in neuroblastoma tumours that 
relapsed within five years, which also indicates that NBPF1 might suppress the 
development of neuroblastoma. More importantly, induced NBPF1 expression in human 
colon cancer cells decreased their clonal growth in a soft agar assay, demonstrating that 
NBPF1 can act as a TSG, at least in colon cancer (Vandepoele et al., 2008). Like 
neuroblastoma, colon cancer is characterised by frequent deletions or translocations of 1p36 
(Schwab et al., 1996). Indeed several reports indicate that the same TSG might be implicated 
in both neuroblastoma and colon cancer (Kong et al., 1997; Reyes-Mugica et al., 1998). 
3. The NBPF gene family 
3.1 Structure of the NBPF gene family 
The cloning of the breakpoints of the constitutional translocation in a neuroblastoma patient 
revealed that this translocation had disrupted NBPF1 (see section 2). This gene is a member of 
the NBPF gene family, which is located primarily on duplicated regions of chromosome 1 
(Figure 2A). In neuroblastoma, these regions frequently contain aberrations. For instance, one 
third of primary neuroblastoma tumours carry a deletion of the 1p36 region (White et al., 2005).  
The NBPF genes have a repetitive structure with high intergenic and intragenic sequence 
similarity, both in coding and non-coding regions (Vinogradova et al., 2002; Vandepoele et 
al., 2005). The NBPF1 gene consists of 25 coding exons, but on the basis of their high 
sequence identities, these exons can be classified into 14 different exon types (Figure 2B). All 
other NBPF genes contain variable numbers of some or all of the exon types present in 
NBPF1, but some genes also contain exons without significant homology to the NBPF1 
exons. The NBPF gene family consists of 24 members located primarily on three regions of 
chromosome 1, namely, 1p36, 1p12 and 1q21, but two members, NBPF21P and NBPF22P, are 
located on chromosomes 3p and 5q, respectively. 
Several members of this gene family are abundantly expressed in different human cell lines 
and human tissues, but no discernable orthologs could be found in the genomes of mouse or 
rat. Nevertheless, the NBPF genes do not appear to be restricted to primates because 
sequences with low but significant homology to NBPF have been identified in bovine and 
canine genomes (Vandepoele et al., 2005). 
We previously analysed the genomic organisation of the NBPF gene family (Vandepoele et 
al., 2005). For that analysis, we used the reference sequence of the human genome of the 
NCBI build 35, which is an improvement over the first release because it contains only 341 
gaps (IHGSC 2004) instead of the 150,000 gaps that were present in the first draft version. 
However, the NBPF genes are located in regions that are refractory to all standard 
sequencing efforts. In this analysis, we obtained numerous small contigs that contained only 
partial NBPF genes. To provide an up-to-date description of the NBPF genes in the human 
genome reference sequence, we now report on the analysis of NBPF sequences in the current 
human genome release (Build 37.2). 
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Fig. 2. Genomic overview of the NBPF gene family.  
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Legend to figure 2: Genomic overview of the NBPF gene family. A/ Ideogram of human 
chromosome 1 showing the localisation of the NBPF genes. The arrow in front of each gene 
indicates its orientation in the chromosome. The colour of the gene symbol indicates 
whether it is full-length (green; start and stop codons present in one continuous ORF in the 
predicted cDNA), partial (red; due to gaps in the genomic sequence), or a pseudogene 
(black, P). Vertical lines indicate whether genes are present in a single genomic contig of the 
human genome assembly (NCBI Build 37.2). The two genes not linked to the ideogram, 
NBPF21P and NBPF22P, are located on other chromosomes. B/ The open reading frames of 
the different NBPF genes were assembled in silico based on cDNA sequences. NBPF4 to 
NBPF6 and NBPF22P contain exons with no significant homology to exons present in 
NBPF1. These are shown as gray boxes with letters instead of numbers. NBPF8 contains a 
deletion of two nucleotides in the first coding exon, which results in a frameshift mutation. 
Due to skipping of the type-2 exon in several NBPF8 transcripts, this frameshift often does 
not result in a premature stop. NBPF-X sequences are new NBPF members that still lack an 
official gene symbol. Frameshift and nonsense mutations in pseudogenes are indicated by 
asterisks. Three consecutive dots indicate the presence of gaps in the current genomic 
assembly (Updated from Vandepoele et al., 2005). 
In addition to the 22 NBPF genes we identified before (Vandepoele et al., 2005), two 
additional NBPF genes are currently present in GenBank: NBPF23 and NBPF24. Copy 
number variations of NBPF23 were recently shown to be involved in neuroblastoma (see 
below) (Diskin et al., 2009). In our previous analysis, we only focused on the coding exons, 
and so the 5’UTR was not properly annotated in the databases. However, the NBPF23 
sequences are upstream of the NBPF17P encoding exons at a similar distance as the 5’UTR 
exons of NBPF1 are from its coding sequences. We therefore believe that the NBPF23 gene is 
not a novel gene but is the 5’UTR of NBPF17P. We described NBPF17P as a pseudogene 
because it contains nonsense mutations in the normal coding sequence (Vandepoele et al., 
2005). In view of that, it is interesting that Diskin et al. (2009) found that this sequence is 
strongly expressed in several tissues, which indicates that this “pseudogene” might have a 
function. The other new NBPF member in GenBank is NBPF24, but this is still a hypothetical 
sequence predicted from a fragment of genomic DNA (see below). 
The short arm of chromosome 1 contains two regions that harbour NBPF genes. The 1p36 
locus contains the NBPF1 gene. Additionally, one functional gene (NBPF3) and a partial 
duplication of this gene (NBPF2P) are located proximal to NBPF1. Closer to the centromere 
on 1p12, there is a second cluster of NBPF genes (NBPF4 to NBPF7). These genes are very 
similar to each other and make up a separate branch of the NBPF evolutionary tree 
(Vandepoele et al., 2005). The sequences of these two clusters were not changed in the most 
recent human genome reference sequence. The updated version of the human genome 
reference sequence has undergone numerous changes in chromosome 1q. Overall, it now 
contains more NBPF sequences than the previously published sequence. The NBPF8 gene 
was the most proximal NBPF gene in our old analysis, but it is now preceded by a novel 
NBPF member, which we call NBPF-X1. This is the longest NBPF gene we have observed so 
far, with a size of 77 kb and a cDNA of 11 kb. As there is still a gap in the genomic sequence 
on the 5’ side of NBPF-X1, the gene and its derived cDNA are presumably even longer. 
Distal to NBPF-X1, NBPF8 is an aberrant member of the NBPF gene family. Deletion of two 
nucleotides in its first coding exon causes a frameshift. However, this frameshift can be 
rescued by an alternative splicing event that excludes the second coding exon from the 
mature mRNA. NBPF9, NBPF10 and NBPF11 are identical to those in the old analysis. Like 
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NBPF-X1, NBPF10 contains numerous repeats of the 3’ exons. NBPF11 contains a frameshift 
mutation in one of its last exons, but this gene is nevertheless expressed in a variety of 
tissues, and hence, we consider it a functional gene. NBPF11 is followed by a second new 
NBPF gene, NBPF-X2. As the 5’ end of this gene is located near a gap in the contig, only a 
partial sequence is available. In our previous analysis, the sequence of the NBPF12 gene was 
incomplete, with only nine consecutive exons in an uninterrupted contig. In the current 
genome sequence, the complete NBPF12 gene is present and contains 77 exons. This is 
followed by NBPF13P, a pseudogene with numerous nonsense mutations in different exons, 
and the new NBPF24. Interestingly, NBPF24 is an almost identical copy of NBPF11 and 
contains the same frameshift mutation in one of its last exons. The following gene, NBFP14, 
has not changed in the current assembly, but it is followed by the last new NBPF gene, 
NBPF-X3. Like other new members, NBPF-X3 is also composed of many repetitions of the 
standard NBPF exon types. The identical NBPF15 and NBPF16 genes are contained in the 
last contig on chromosome 1q, together with the NBPF17P and NBPF18P pseudogenes. In 
our previous analysis, NBPF19 and NBPF20 were not positioned on chromosome 1. In the 
current assembly, these sequences are no longer represented. Since the 1q21 region is prone 
to copy number variation and the human genome reference sequence is derived from 
different haplotypes, it is possible that NBFP19 and NBPF20 are not true paralogs of the 
current NBPF genes, but simply variants of other NBPF genes in another haplotype. 
In addition to the NBPF sequences on chromosome 1, two other regions in the human 
genome contain NBPF-like sequences: 3p22.3 (NBPF21P) and 5q14.2 (NBPF22P). These 
sequences have only limited homology to the NBPF genes on chromosome 1 but share a 
common origin and are hence included in the NBPF family. 
Analysis of the predicted protein sequences showed that several pairs of exon types encode 
a novel protein domain, called the NBPF repeat. The NBPF repeat comprises a PFAM 
protein domain of unknown function, called DUF1220 (Vandepoele et al., 2005), and we will 
refer to this repeat as the NBPF/DUF1220 repeat. It is always built of two exons and is 
present in multiple copies in the different NBPF proteins. It is also present as a single copy 
with lower homology in the human PDE4DIP gene encoding myomegalin (Figure 3) (Verde 
et al., 2001). Myomegalin is a centrosomal protein and contains, besides its NBPF/DUF1220 
domain, some regions that show homology to CDK5RAP2, a gene that lacks 
NBPF/DUF1220 sequences. Mutation of CDK5RAP2 has been implicated in microcephaly 
(Bond & Woods, 2006). There is recent evidence for involvement of the NBPF/DUF1220 
repeat in human evolutionary adaptation, cognitive function, and disease, including 
neuroblastoma (see below). Other than the novel NBPF/DUF1220 repeat, there are no 
known protein domains in the NBPF proteins. 
3.2 The NBPF gene family and human evolution 
Several regions on chromosome 1 consist of recently duplicated sequences, and the NBPF 
gene family is located primarily on such segmental duplications (Vandepoele et al., 2005). 
Segmental duplications, also known as low copy repeats, are duplicated blocks of genomic 
DNA longer than 1 kbp and with high sequence identity, and they typically map to two or 
more locations in the genome (Marques-Bonet et al., 2009b). The number of base pairs 
mapping to high-identity duplications are similar in the human and mouse genomes, but 
the segmental duplications in mouse are tandemly organised, whereas in humans most of 
them are interspersed (She et al., 2008). Additionally, human segmental duplications tend to 
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Fig. 3. Exon organisation of the NBPF1 gene and the predicted domain structure of the 
translated NBPF1 protein. 
A/ Analysis of the predicted NBPF protein sequences showed that each of several pairs of 
exon types encodes a novel protein domain, called the NBPF repeat. The NBPF repeat 
comprises a PFAM protein domain of unknown function, called DUF1220 (see C). It is 
always built of two exons and is present in multiple copies in the different NBPF proteins. 
Three coiled-coil regions were predicted in the N-terminal domain of the NBPF1 protein. 
Each coiled-coil is encoded by a combination of the type-2 exon and a part of the type-3 
exon. B/ Schematic representation of the open reading frame of the NBPF1 gene as 
predicted from the human genome sequence (NT_004873.16) and present in an isolated 
cDNA sequence (AY894575) derived from this gene. The isolated cDNA contains multiple 
copies of exon types 10, 11, 12 and 13, which are present only once in the genomic sequence. 
The several exon couples that constitute the NBPF/DUF1220 repeat are shown in white 
boxes at the bottom. C/ Amino acid alignment of the different NBPF repeats present in the 
NBPF1 protein. A homologous sequence was isolated from the draft version of the bovine 
genome and assembled in silico (depicted as AC157123). The bottom sequence is derived 
from one of the human homologs of rat myomegalin (AB007923; AA 1564-1654). The black 
line denotes the exon boundaries, whereas the red lines denote the PFAM protein domain of 
unknown function, DUF1220 (Adapted from Vandepoele et al., 2005, Oxford Journals (2005), 
reproduced by permission). 
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be enriched in spliced transcripts (She et al., 2008) and show a higher sequence identity 
(Marques-Bonet & Eichler, 2009). It has been shown that segmental duplications, together 
with retrotransposons, account for the large-scale structural variations in primate genomes. 
Humans and other great apes share interspersed duplications, but a burst of segmental 
duplications also occurred in the common ancestor of humans and African great apes 
(Marques-Bonet et al., 2009a). 
As segmental duplications appeared quite recently, it is presumed that genes residing in 
these regions played a role in evolution. The morpheus gene family, for example, is found 
only in humans and African apes and is located in segmental duplications on chromosome 
16 (Johnson et al., 2001). These genes were repeatedly duplicated and positively selected for 
during primate evolution and, therefore, presumably played a role in speciation events. 
Amino acid replacements in putative protein-encoding exons of this gene family occurred 
after the separation of human/great-ape lineages from orangutan and after the divergence 
of human and chimpanzee lineages. This points to adaptive evolution of the morpheus gene 
family during the emergence of humans and African apes (Johnson et al., 2001). It is 
becoming clear that lineage-specific gains and losses in gene copy number have emerged as 
an important aspect of primate genetic variation (Cheng et al., 2005). An array-based 
comparative genomic hybridisation that surveyed gene duplication and losses across 10 
primate species identified over 4,000 genes that show lineage-specific copy-number gains 
and losses (Dumas et al., 2007). Those genes exhibiting lineage-specific copy number 
changes are likely involved in the phenotypic differences that distinguish these primate 
lineages. Interestingly, NBPF/DUF1220 sequences show human lineage-specific copy 
number increases (Dumas et al., 2007), consistent with previous reports (Fortna et al., 2004; 
Vandepoele et al., 2005; Popesco et al., 2006). Different experiments indicated that the 
number of NBPF/DUF1220 repeats was very large in humans, reduced in African great 
apes, further reduced in orangutan and Old World monkeys, single-copy in non-primate 
mammals, and absent in non-mammalian species (Popesco et al., 2006). The dramatically 
elevated copy number in humans indicates the importance of the NBPF/DUF1220 repeat in 
human evolution. Moreover, comparison of the human chromosome 1 with that of 
chimpanzee revealed a remarkable human 3-mer higher order repeat (HOR) organisation 
based on an ~1.6-kbp primary repeat unit fully embedded within the NBPF genes (Figure 
4A). This HOR pattern is not found in chimpanzee and shows some peculiarities, namely 
that the repeat unit is much longer than most primary repeat units identified so far and that 
the HOR is fully embedded within a gene. Additionally, the total absence of tandem repeats 
of NBPF HOR copies in chimpanzees while 47 tandem repeat HOR copies are present in 
human genomes reflects a human accelerated HOR pattern that distinguishes humans from 
nonhuman primates (Figure 4B) (Paar et al., 2011). 
It has been shown that genes with an important contribution to human evolution, like the 
NBPF gene family, are located in human segmental duplications, which are frequently 
organised around core duplicons (Jiang et al., 2007). Comparison of chimpanzee and man 
shows that new lineage-specific segmental duplications map preferentially near shared 
ancestral duplications, a phenomenon called duplication shadowing (Cheng et al., 2005). 
Unique genes mapping near these duplication blocks have a ten-fold higher probability of 
becoming duplicated than other randomly distributed regions. The NBPF/DUF1220 
domains are among the few core duplicons that exist in the human genome and appear to be 
responsible for much of the duplicated sequences in the pericentromeric region of 
chromosome 1 (Jiang et al., 2007). These large, high-identity duplication blocks are prone to 
rearrangements that lead to the formation of both harmless and pathogenic copy number 
variations, as discussed in the following section. 
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Fig. 4. Schematic illustration of the NBPF HOR copy. 
A/ The NBPF HOR copy consists of three 1.6-kbp primary repeat units organised into 
~4,770-bp secondary repeat units. The divergence between the three consensus monomers 
(m01, m02 and m03) is between 15 and 20%, whereas the average divergence between the 3-
mer HOR copies is mostly below 0.5%, which is characteristic of a well-developed HOR 
pattern. Figure not drawn to scale. B/ The total number of NBPF monomers and the number 
of NBPF HOR copies (both tandemly organised and dispersed) gradually increases with 
evolutionary development, but the tandem repetition of the NBPF HOR copies is exclusive 
to humans (Modified after Paar et al., 2011, Oxford Journals (2011), reproduced by 
permission). 
3.3 The NBPF gene family shows frequent copy number variations that are sometimes 
associated with pathologies, including neuroblastoma 
As previously discussed, primate segmental duplications are larger, more complex and 
more interspersed than those in other mammalian genomes. This pattern promotes genomic 
instability and leads to considerable copy number variation (Bailey & Eichler, 2006). A copy 
number variation (CNV) is a structurally variable region of DNA longer than 1 kbp present 
in the genomes of humans (Redon et al., 2006), primates and many other species (Graubert et 
al., 2007; Chen et al., 2009). In these genomes, the DNA region is present in various copy 
numbers due to gains and losses of genomic DNA. Surprisingly, as much as 12% of the 
human genome is copy number variable, and despite efficient DNA repair, the rates of de 
novo CNVs are at least 100 to 10,000 fold greater than rates of point mutations (Lupski, 
2007). 
Nonallelic homologous recombination between low-copy repeats that flank unique genomic 
segments changes the organisation of the genome and is thought to be one of the main 
mechanisms that give rise to CNVs (Inoue & Lupski, 2002). Several studies indicate that the 
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NBPF gene family is polymorphic within the human population (Database of Genomic 
Variants). Analysis of the copy number differences between the genomes of 159 human 
individuals showed that the NBPF gene family is one of the most variable gene families in 
humans (Sudmant et al., 2010). Sudmant et al. (2010) also showed that the NBPF gene 
duplicates are underrepresented in the human reference genome because no individual 
examined exhibited a copy number less than or equal to the copy number in the reference 
genome. Paralog-specific copy number genotyping distinguished two distinct classes of 
paralogs: one group is mostly copy-invariant in humans, and the other group is extensively 
copy number variable with some bias toward gain or loss. The NBPF gene family showed a 
paralog-specific copy number variation, and certain paralogs (NBPF1) were frequently 
amplified, extremely variable, and stratified by population, whereas other paralogs (NBPF7) 
were nearly fixed and diploid (Sudmant et al., 2010). Taken together, these data clearly show 
that the NBPF gene family is polymorphic in the human population. 
The functional implications of these structural variations in the human genome can be of 
great importance: not only are they an important source of genetic diversity between 
individuals, they can also affect an individual’s susceptibility to disease. Several diseases, 
such as lupus with glomerulonephritis and Crohn’s disease, have been linked to CNV of 
FCGR3B and HBD-2, respectively. It has been shown that a low copy number of FCGR3B (Fc 
fragment of IgG, low affinity IIIb, receptor) predisposes to glomerulonephritis, an 
immunologically mediated renal disease (Aitman et al., 2006), whereas individuals with less 
than three copies of the human beta-defensin 2 (HBD-2) gene have a significantly higher risk 
of developing Crohn’s disease than individuals with four or more copies (Fellermann et al., 
2006). In neuroblastoma, an inherited copy number variation was shown to be associated 
with this childhood cancer. Indeed, Diskin et al. (2009) found that a common deletion 
polymorphism spanning less than 145 kbp at 1q21.1 is associated with neuroblastoma. 
Validation by quantitative PCR, fluorescent in situ hybridisation, and analysis of matched 
tumour specimens showed that this CNV is a heritable genetic variation. Interestingly, the 
5’UTR of NBPF17P (NBPF23; see above) is located in this CNV. Quantitative PCR showed 
that this NBPF paralog is expressed in a variety of fetal and adult tissues, but the strongest 
expression was observed in fetal brain and fetal sympathetic nervous tissue. Importantly, 
these experiments showed that the expression level was strictly correlated with the CNV 
state in neuroblastoma cells (Diskin et al., 2009). Recently, it has become clear that CNVs in 
the 1q21.1 region are associated not only with neuroblastoma, but also with an increasing 
number of other pathologies. Intriguingly, these copy number gains or losses either 
encompassed or flanked members of the NBPF gene family, emphasising the possible 
involvement of the NBPF gene family in human disease. CNVs at these genomic loci have 
been found in patients with mental retardation and congenital anomalies (Mefford et al., 
2008), autism (Sharp et al., 2006; Szatmari et al., 2007) and schizophrenia (Stefansson et al., 
2008). Autism and schizophrenia can be described as diametric conditions because 
reciprocal variants of the same genomic sequences, namely duplication and deletion, 
represent risk factors for these respective psychiatric conditions. Additionally, autism and 
schizophrenia are associated with developmentally enhanced and reduced brain growth, 
respectively (Crespi et al., 2009). A study of 1q21.1 CNVs and brain size found that deletions 
of the 1q21 region are associated with microcephaly, which is characterised by an 
abnormally small head, whereas duplications of this region are associated with 
macrocephaly, which is characterised by an abnormally large head (Brunetti-Pierri et al., 
2008). Notably, the most striking trend in human evolution is the rapid increase in brain size 
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over the past 3–4 million years, and the associated increase in complexity and cognitive 
capacity (Mekel-Bobrov et al., 2007). Because NBPF/DUF1220 is present in remarkably more 
copies in the human genome than in other primates (Vandepoele et al., 2005; Popesco et al., 
2006), it was hypothesised that the NBPF/DUF1220 copy number is correlated with brain 
size (Dumas & Sikela, 2009). Moreover, these data support the hypothesis that 
NBPF/DUF1220 domains are involved in the difference in brain size between autistic and 
schizophrenic populations and between macrocephalic and microcephalic populations. 
Therefore, NBPF/DUF1220 repeats could have played an important role in human 
evolution and in the associated increase in brain size. On the other hand, the selective 
advantage conferred by the increased number of NBPF/DUF1220 domains might have 
favored retention of the highly unstable 1q21.1 region, resulting in many recurrent 
rearrangements and leading to a spectrum of disorders of the human brain and to 
developmental defects (Dumas & Sikela, 2009). 
4. NBPF promoter analysis 
Gene duplication has generally been viewed as a primary mechanism for the origin of 
evolutionary novelties (Ohno, 1970). In most cases, duplication is not limited to the coding 
sequence but encompasses the regulatory region as well. Alternatively, new genes can 
acquire a regulatory region from a nonhomologous gene (Usakin et al., 2005). We found 
evidence that the regulatory region of the NBPF1 gene was obtained from an unrelated 
gene, called EVI5 (ecotropic viral integration site 5) (Vandepoele et al., 2009). EVI5 was 
originally identified through its involvement in a constitutional chromosome 
translocation in a patient with stage 4S neuroblastoma (Roberts et al., 1998). EVI5 is a 
centrosomal protein during interphase, but it relocalises to the midbody during late 
phases of mitosis. Its disruption leads to incomplete cell division and formation of 
multinucleate cells (Faitar et al., 2005). EVI5 also exists in a protein complex with GTP-
bound Rab11 and functions as a GTPase-activating protein for this small GTPase 
(Dabbeekeh et al., 2007). Additionally, EVI5 is critical during interphase for the regulation 
of cyclin accumulation. It functions by stabilising the anaphase-promoting complex 
inhibitor, Emi1. RNA interference with EVI5 levels resulted in cell-cycle arrest and 
abnormal centrosome numbers in vivo, suggesting that EVI5 might not only regulate 
cyclin accumulation during interphase but also contribute to timing mechanisms to 
ensure mitotic fidelity (Eldridge et al., 2006). 
The human EVI5, located on chromosome 1p22, is transcribed as two isoforms differing in 
their transcription initiation sites and first exons. Intriguingly, the promoter of NBPF1 shows 
homology only to the promoter used to control the expression of human isoform 2 of EVI5 
(called EVI5NBPF), but not the promoter of isoform 1 (called EVI5ALT) (Figure 5) (Vandepoele 
et al., 2009). 
The extensive sequence homology in the promoter regions of different NBPF paralogs 
shows that the recruitment of the promoter from EVI5NBPF occurred before expansion of the 
NBPF gene family. Phylogenetic analysis of the NBPF and EVI5NBPF core promoter 
sequences showed that promoter duplication occurred after the split between simians and 
prosimians, but before divergence between Old World and New World monkeys, and that 
positive selection played a role in the evolution of the NBPF1 promoter in simians 
(Vandepoele et al., 2009). 
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Fig. 5. Sequence homology between the promoter regions of different NBPF paralogs and 
the promoter regions of EVI5. Expression of the human EVI5 gene is controlled by two 
promoters: EVI5ALT controls the expression of isoform 1 and EVI5NBPF controls the 
expression of isoform 2. Arrows indicate the positions of these transcription initiation sites 
on the reverse strand of chromosome 1, and their first exons are represented by blue boxes 
on the top line. A region of 20 kbp flanking the transcription initiation site of human and 
mouse EVI5NBPF and different NBPF paralogs was aligned by the AVID algorithm in the 
Vista Genome browser. The promoter of NBPF1 and its paralogs shows homology only with 
the promoter of human EVI5 that is used to control the expression of isoform 2 (EVI5NBPF) 
but not the one for isoform 1 (EVI5ALT). The homology between the human and mouse EVI5 
sequences is confined mainly to the two regions corresponding to the putative promoter 
regions. No official gene symbol is available for NBPF** (Adapted from Vandepoele et al., 
2009, Oxford Journals (2009), reproduced by permission). 
The expression patterns of NBPF and EVI5 in a panel of human cell lines are very similar, 
and the expression of both genes was decreased in neuroblastoma cell lines in which there is 
1p36 loss of heterozygosity. Nevertheless, the mechanism of this decreased expression level 
was due to use of a different transcriptional and posttranscriptional regulation. Whereas 
EVI5 was epigenetically silenced, treatment of the neuroblastoma cell lines with puromycin, 
an inhibitor of nonsense-mediated decay, indicated that mutation of the NBPF transcripts 
was probably responsible for decreasing the expression levels. These data together show 
that despite the almost identical promoter sequences and very similar expression patterns, 
regulation of NBPF and EVI5 genes in neuroblastoma cell lines can occur by different 
mechanisms (Vandepoele et al., 2009). 
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5. NBPF-interacting proteins  
Many genes perform their functions by interaction of their encoded proteins with other 
proteins. The search for NBPF-interacting proteins revealed two hits so far: chibby and 
clusterin, which together can form a tri-molecular complex with NBPF1 (Vandepoele et al., 
2010). Interestingly, both NBPF1 and clusterin are candidate tumour suppressors for 
neuroblastoma (Vandepoele et al., 2008; Chayka et al., 2009). This suggests that the 
interactions between these three proteins are functionally important. 
5.1 Chibby 
Chibby (Cby) is a 15-kDa protein that has been strongly conserved throughout evolution 
from fly to human. It was originally identified as an inhibitor of the canonical Wnt-β-catenin 
pathway (Takemaru et al., 2003). Cby interacts with the C-terminal activation domain of β-
catenin and blocks its transcriptional activation potential by two mechanisms. First, it 
competes with T cell factor/lymphoid-enhancer factor (TCF/LEF) transcription factors for 
binding with β-catenin (Takemaru et al., 2003). Second, in cooperation with 14-3-3 adaptor 
proteins, it facilitates nuclear export of β-catenin (Li et al., 2008). Inhibition of the Wnt-β-
catenin pathway is necessary for cardiomyocyte differentiation, proliferation and repair, and 
Cby has been implicated in facilitating cardiomyocyte differentiation (Singh et al., 2007). 
Additionally, several molecules of the Wnt-β-catenin pathway play important roles in the 
inhibition of adipogenesis, and different findings indicate that Cby is required for adipocyte 
differentiation (Li et al., 2007). Cby also plays a role in other processes. Reports on the 
binding of Cby to polycystin-2 (Hidaka et al., 2004) and on the Cby knockout mouse 
(Voronina et al., 2009; Love et al., 2010) implicate Cby in the development of motile airway 
cilia. Germline inactivation of Cby resulted in complete absence of mucociliary transport due 
to scarcity of motile cilia in the nasal epithelium (Voronina et al., 2009). In a follow-up study, 
characterisation of the lung morphology of Cby knockout mice showed that Cby-/- lungs 
were normal at birth, but alveolar airspace became enlarged, proliferation became reduced, 
and lung epithelial cells differentiated abnormally, which together affected pulmonary 
function (Love et al., 2010). Both the lungs and nasal epithelia of Cby knockout mice showed 
increased expression of two direct β-catenin target genes, namely Axin2 and CyclinD1, but it 
is not clear whether the ciliary phenotypes are related to the modest elevation of these Wnt 
related genes, since no change in the localisation of certain components of the Wnt-β-catenin 
pathway was observed. Presence of endogenous Cby at the base of cilia and the phenotypes 
related to the loss of Cby show that Cby is important in ciliogenesis (Voronina et al., 2009; 
Love et al., 2010). 
Neuroblastoma is a disease of the sympathoadrenal lineage of the neural crest, and these 
tumours can develop anywhere in the sympathetic nervous system. At least three key 
pathways regulate the formation, migration and differentiation of the neural crest cells: the 
bone morphogenetic protein (BMP) pathway (Barembaum & Bronner-Fraser, 2005), the 
fibroblast growth factor pathway (Sauka-Spengler & Bronner-Fraser, 2008) and the Wnt 
signalling pathway (Crane & Trainor, 2006). Wnt signalling plays an important role in 
neural crest cells. For example, mouse embryos in which Wnt1 and Wnt3 were knocked out 
displayed severe loss of neural crest cells (Varga & Wrana, 2005). In addition, conditioned 
medium of cells overexpressing wingless (Drosophila homolog of Wnt1) could induce avian 
neural crest cells (Garcia-Castro et al., 2002). Aberrant regulation of the embryonic 
developmental Wnt pathway has been implicated in many solid childhood tumours 
(reviewed in Koesters & Doeberitz, 2003), but a clear role for Wnt signalling in 
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neuroblastoma has remained elusive. Nevertheless, there is mounting evidence that the Wnt 
pathway is involved in neuroblastoma (Table 1). 
The MSX1 homeobox transcription factor functions as an intermediate between the BMP 
and Wnt signalling pathways to ensure proper differentiation of the neural crest cells. 
Elevated expression of BMP in non-neuronal ectoderm switches on the neural crest 
differentiation program and induces the expression of MSX1, which leads to induction of 
the expression of BMP and Wnt in neural crest cells (Ramos & Robert, 2005). Msx genes 
might regulate Wnt1 expression at the dorsal midline of the neural tube (Bach et al., 2003). 
Additionally, MSX1 overexpression in the MYCN-amplified neuroblastoma cell line SJNB8 
induced the expression of four Wnt inhibitor genes: Dickkopf 1 (DKK1), Dickkopf 2 (DKK2) 
and Dickkopf 3 (DKK3) and secreted frizzled-related protein 1 (SFRP-1) (Revet et al., 2010). 
Analysis of the expression profiles of MSX1, DKK1, -2, -3 and SFRP-1 in a series of 
neuroblastic tumours showed a significant and positive correlation between MSX1 and 
DKK2 expression and between MSX1 and DKK3 expression. Additionally, stronger DKK2 
and DKK3 expression correlated with a significantly better prognosis. Expression profiling 
of neuroblastic tumours and cell lines for the different Wnt family genes showed that both 
the canonical Wnt3a and the non-canonical Wnt5 were strongly expressed and that they 
could activate upstream Wnt signalling in neuroblastoma cells by phosphorylating the 
dishevelled co-receptor DVL3 (Revet et al., 2010). The importance of DKK3 in neuroblastoma 
was already shown in previous reports, in which DKK3 was implicated as a marker for 
neuroblastic tumour maturation and was shown to be down-regulated by MYCN (Bell et al., 
2007; Koppen et al., 2008). 
Additionally, β-catenin has been shown to be strongly expressed and aberrantly localised in 
the nucleus in high-risk neuroblastoma cells without MYCN amplification (Liu et al., 2008). 
Expression profiling of primary neuroblastoma tumours demonstrated increased expression 
of WNT ligands (WNT1, WNT6, WNT7A, WNT10B), DVL1 and TCF7 in high-risk 
neuroblastoma tumours without MYCN amplification. Also several β-catenin target genes,  
 
DKK1 interacts with co-receptor LRP
DKK2 interacts with co-receptor LRP
DKK3 interacts with co-receptor LRP induced upon overexpression of Msx1 in NB cell line and downregulated by MYCN
SFRP1 secreted antagonist induced upon overexpression of Msx1 in NB cell line
Wnt3a ligand
Wnt5 ligand
B-catenin key mediator localized in the nucleus in NB cells without MNA
Wnt1 ligand increased expression in primary NB tumors without MNA
Wnt6 ligand
Wnt7A ligand
Wnt10B ligand
DVL1 co-receptor
TCF7 transcription factor
Myc target gene
CD44 target gene
FZD1 seven-transmembrane receptor
MDR1 target gene
strongly expressed in neuroblastic tumors and cell lines 
increased expression in primary NB tumors without MNA
increased expression in chemoresistant NB cell lines and in relapsed patients
Gene Function Neuroblastoma
induced upon overexpression of Msx1 in NB cell line
 
Table 1. Wnt signalling is important in neuroblastoma tumourigenesis and 
chemoresistance.Schematic representation of different Wnt signalling components implicated 
in neuroblastoma. NB: neuroblastoma; MNA: MYCN amplification. See text for references. 
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e.g. MYC and CD44, were found to be coordinately upregulated in high-risk neuroblastomas 
without MYCN amplification in comparison to high-risk MYCN-amplified or intermediate-
risk neuroblastomas (Liu et al., 2008). 
Another study implicated the Wnt-β-catenin pathway in neuroblastoma chemoresistance 
(Flahaut et al., 2009). Gene expression profiling of two doxorubicin-resistant neuroblastoma 
cell lines identified the frizzled1 Wnt receptor (FZD1) gene as the most strongly 
overexpressed transcript in both cell lines in comparison with their sensitive parental cell 
lines. FZD1 silencing resulted in significant restoration of drug sensitivity and induced a 
parallel strong decrease in the expression of MDR1 (Flahaut et al., 2009), another β-catenin 
target gene frequently associated with the resistance of neuroblastoma tumours to 
chemotherapeutic drugs (Haber et al., 1997). Moreover, FZD1 and/or MDR1 expression was 
significantly enhanced in the group of relapsed patients after chemotherapy, whereas no 
significant increase in expression was measured in the group of non-relapsed patients 
(Flahaut et al., 2009). 
These data indicate that Wnt signalling is important in neuroblastoma tumourigenesis and 
chemoresistance (overview in Table 1). Therefore, we hypothesise that important players in 
the Wnt-β-catenin pathway might play important roles in neuroblastoma. But nothing is 
known yet about the role of Cby in neuroblastoma tumourigenesis or chemoresistance, and 
further investigation is needed. 
5.2 Clusterin 
Clusterin (CLU), also known as apolipoprotein J, is a heterodimeric sulfated glycoprotein 
that is expressed in most human tissues and body fluids and is associated with many 
biological activities, including regulation of apoptosis and cancer (Trougakos & Gonos, 
2002). Research on CLU function and its relation to tumourigenesis has been intensive, but 
many contradictory data have been reported. These contradictions can be explained mainly 
by the existence of three protein isoforms with different sub-cellular localisations and 
biological functions (Rizzi & Bettuzzi, 2010). 
The most extensively studied form of CLU is the secreted form (sCLU), which is a 
glycosylated heterodimer present in almost all physiological fluids. sCLU is exported from 
the cell and released in secretions, in which it acts as an extracellular chaperone 
(Humphreys et al., 1999). Cytoplasmic clusterin has been shown to inhibit apoptosis by 
interfering with Bax activation in the mitochondria (Zhang et al., 2005). Clusterin binds and 
stabilises the Ku70-Bax protein complex and serves as a cytosolic retention factor for Bax. 
Depletion of clusterin disrupts the Ku70-Bax complex and triggers Bax activation and its 
relocalisation to the mitochondria (Trougakos et al., 2009). Cytoplasmic clusterin also 
promotes tumour cell survival by cooperating with c-Myc during transformation (Zhang et 
al., 2005). Additionally, a large amount of CLU confers resistance to cytotoxic agents on 
different cancer cell types (Lourda et al., 2006). However, a nuclear form of clusterin 
originating from an alternative translation start site has been shown to be proapoptotic in 
prostate cancer cells (Moretti et al., 2007), breast cancer cells (Leskov et al., 2003) and 
neuroblastoma (Yang et al., 2000). 
The main question is whether clusterin is a positive or negative modulator of mammalian 
tumourigenesis. It is becoming clear that CLU can act either as a tumour suppressor 
(Caporali et al., 2004; Chayka et al., 2009) or as a tumour promoter (Lourda et al., 2006), but 
the time-course of the disease and the selection pressures imposed on the cancer by 
chemotherapy or other treatments have to be taken into account. 
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Clusterin knockout mice are more prone to autoimmune myocarditis (McLaughlin et al., 
2000) and to transformation of the prostate epithelium (Bettuzzi et al., 2009). In homozygous 
knockout mice, the normal portion of prostate tissue is characterised by stronger expression 
of the proliferation marker Ki67 and shows activated NF-κB signalling, but this was not 
observed in wild type mice (Bettuzzi et al., 2009). Additionally, in TRAMP mice, a transgenic 
animal model of prostate cancer (Greenberg et al., 1995), the CLU gene is dramatically 
downregulated during onset and progression of prostate cancer (Caporali et al., 2004). 
Crossing of these TRAMP mice with the clusterin knockout mice led to development of a 
more advanced invasive disease in the progeny, confirming the role of CLU as a negative 
tumour modulator in prostate cancer (Bettuzzi et al., 2009). 
On the contrary, overexpression of clusterin in LNCaP prostate cancer cells conferred 
resistance to both androgen ablation in vivo and cytotoxic chemotherapy (Miyake et al., 
2000c). Additionally, the administration of clusterin antisense oligonucleotides in prostate 
cancer xenograft models delayed progression to androgen independence and enhanced 
chemosensitivity (Miyake et al., 2000b). A human clusterin antisense oligonucleotide (OGX-
011) synergistically enhanced the cytotoxic effects of paclitaxel in human xenografts of 
prostate cancer (Miyake et al., 2000a). This antisense oligonucleotide is currently undergoing 
clinical trials for tumour therapy. The phase I trial demonstrated that OGX-011 is well 
tolerated and that it inhibits clusterin expression in prostate cancer (Chi et al., 2005). The 
phase II trial assessed the effects of combined therapy with androgen ablation and OGX-011 
given prior to radical prostatectomy in patients with metastatic castration-resistant prostate 
cancer. This study showed that the combined therapy was associated with improved 
survival (Chi et al., 2010). 
The biological role of clusterin is controversial in both prostate cancer and neuroblastoma. 
Indeed, also in neuroblastoma it has been shown that clusterin can function both as a 
tumour suppressor gene and as an oncogene. Overexpression of clusterin impaired the 
invasion of neuroblastoma cell lines by inhibiting the NF-κB activity by stabilising IκBs, the 
inhibitors of NF-κB signalling (Santilli et al., 2003). Additionally, Oncomine expression 
analysis (Rhodes et al., 2007) showed a lower expression level of the CLU gene in primary 
human neuroblastomas with MYCN amplification, and further investigation demonstrated 
that MYCN acts as a negative regulator of clusterin expression by inducing transcription of 
the 17-5p~92 microRNA cluster (Chayka et al., 2009). This polycistronic cluster encodes six 
microRNAs (miR-17-5p, -18a, -19a, -19b, -20a and -92) and is homologous to the miRNA 
106a~92 cluster (Mestdagh et al., 2010b). Most miRNAs encoded by this cluster are 
expressed at higher levels in neuroblastoma cell lines overexpressing MYCN or carrying 
MYCN amplification. MYCN transcriptionally induces the expression of the miRNA 17-
5p~92 cluster by directly binding to its promoter. The therapeutic potential of this miRNA 
cluster was demonstrated by injecting a miR-17-5p-specific antagomir into nude mice that 
had been injected with a neuroblastoma cell line with MYCN amplification. Tumour growth 
in vivo was reduced substantially, and this reduction was associated with down-modulation 
of miR-17-5p activity and with a reciprocal increase of both p21 and BIM protein levels. 
Nevertheless, the expression pattern of miR-17-5p in primary tumours is complex, because 
high levels of miR-17-5p expression were detected in both MYCN-amplified and non 
MYCN-amplified tumours (Fontana et al., 2008). Additionally, it has been demonstrated that 
miR-17-5p~92 dampens TGF-β signalling by acting both upstream and downstream of 
pSMAD2/SMAD4 (Mestdagh et al., 2010a). This finding further underscores its ability to 
regulate multiple components of the same pathway. 
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When MYCN-transgenic mice were crossed with clusterin knockout mice, the progeny 
showed reduced tumour-free survival, active NF-κB signalling, and epithelial to 
mesenchymal transition (Chayka et al., 2009); this resembles the phenotype of TRAMP mice 
in which CLU was homozygously deleted (Bettuzzi et al., 2009). These data indicate that 
clusterin functions as a TSG for neuroblastoma, even though several reports indicate that it 
can promote neuroblastoma. Treatment with histone deacetylase inhibitors (HDACIs) 
resulted in upregulation of clusterin in different cancer cell lines, including neuroblastoma 
(Liu et al., 2009; Subramanian et al., 2011). Suppression of clusterin in combination with 
high-dose HDACIs synergistically enhanced HDACI-induced cell death through 
cytochome-c-mediated apoptosis in HDACI-resistant cancer cells. Additionally, combining 
OGX-011 with low-dose HDACIs enhanced HDACI-induced growth arrest in both HDACI-
sensitive and -resistant cancer cell lines. Moreover, in mice xenografted with neuroblastoma 
cells, combining OGX-011 and valproate (the only HDACI proven to be safe in young 
children) synergistically inhibited tumour growth in vivo, whereas neither OGX-011 nor 
valproate alone had an effect on tumour progression (Liu et al., 2009). 
 
 
Fig. 6. Proposed model for CLU in tumourigenesis. 
In normal cells and under physiological conditions the basal expression level of CLU in 
benign cells is low and confined to the secreted form of CLU (sCLU) (1). Several apoptotic 
stimuli (2) lead to the production of nuclear CLU (nCLU) (3), which in turn induces 
extensive cell death (4). In the early phases of tumourigenesis, genetic lesions lead to 
acquisition of survival advantages and consequent clonal selection (5). A key step in the 
transformation process is prevention of CLU from entering the nucleus. Cells with high 
levels of cytoplasmic CLU are then selected for, which results in acquisition of a death-
resistant phenotype (6). This phenotype is associated with impaired mitosis (7), which leads 
eventually to genomic instability (8) (Modified after Rizzi & Bettuzzi, 2010, Society for 
Endocrinology (2010), reproduced by permission). 
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Based on these findings, which were observed in both prostate cancer and neuroblastoma, a 
role for clusterin in tumourigenesis has been proposed (Figure 6). This model proposes that 
clusterin acts as a tumour suppressor in the early stages of cancer but can become a tumour 
promoter in the more malignant and advanced stages, namely when tumours become 
resistant to therapy (Rizzi & Bettuzzi, 2010). Under physiological conditions, the basal 
expression level of CLU in benign cells is low and confined to the secreted form of CLU 
(sCLU). Several apoptotic stimuli lead to the production of nuclear CLU (nCLU), which in 
turn induces extensive cell death. At the onset of cancer, early genetic lesions disrupt or 
inactivate apoptotic pathways or lead to the activation of other survival pathways. Under 
these conditions of clonal selection, a key step in the transformation process would be the 
prevention of CLU from entering the nucleus in order to prevent induction of apoptosis. At 
this point, cancer cells are characterised by strong expression of cytoplasmic CLU (cCLU) 
and are therefore resistant to death by cytotoxic therapeutic agents. This resistant phenotype 
can promote cell transformation that leads to late cancer stages associated with impaired 
mitosis, which causes further genomic instability (Rizzi & Bettuzzi, 2010). 
5.3 NBPF1, Chibby and clusterin can form a tri-molecular complex 
A yeast two-hybrid screening with an N-terminal fragment of the NBPF11 protein identified 
Cby as a binding partner of NBPF11 (Vandepoele et al., 2010). This interaction is not 
exclusive to NBPF11 but is common to other NBPF members. For instance, Cby can also 
interact with NBPF1. The interaction was confirmed by other techniques, such as co-
immunoprecipitation and mitochondrial recruitment (Vandepoele et al., 2010). It was shown 
that the coiled-coil region in the N-terminal domain of NBPF interacts with the coiled-coil 
region in the C-terminal domain of Cby. This C-terminal portion of Cby harbours not only 
the binding site for NBPF, but also the binding site for most other known interaction 
partners of Cby, such as β-catenin (Takemaru et al., 2003), polycystin-2 (Hidaka et al., 2004) 
and TC1 (Jung et al., 2006). 
Functional analysis of the interaction showed that NBPF did not influence Cby-mediated 
Wnt signalling, nor did it compete with β-catenin binding to Cby. This indicates the 
presence of two different pools of Cby, one binding to β-catenin and the other binding to 
NBPF, or alternatively, a dimeric Cby complex that can bind simultaneously to β-catenin 
and NBPF. Besides its repressor function in the Wnt pathway, Cby can also play an 
important role in ciliogenesis, as shown in the Cby knockout mouse (see section 5.1). The 
role of NBPF in the formation of cilia remains uncertain, as NBPF1 overexpression did not 
interfere with the formation of primary cilia (Vandepoele et al., 2010). An additional yeast 
two-hybrid screen identified clusterin as a new binding partner for Cby and showed that the 
C-terminus of CLU, which contains a coiled-coil domain, interacts with both the N-terminal 
and C-terminal domains of Cby. Additionally, co-immunoprecipitation experiments in 
HEK293T cells demonstrated that NBPF1, Cby and clusterin can form a tri-molecular 
complex (Figure 7), because all three proteins were co-purified in every setting. 
Since intracellular CLU can be found both in the nucleus and in the cytoplasm (see section 
5.2), the effect of Cby or NBPF or their combination on the subcellular localisation of CLU 
was further investigated, but no difference was observed (Vandepoele et al., 2010). 
The identification of two proteins that interact with NBPF is a clue to the functions of 
NBPF, but further investigation is needed. Anyway, the identification within the complex 
of two proteins (NBPF1 and CLU) as candidate tumour suppressor genes linked to 
neuroblastoma (Vandepoele et al., 2008; Chayka et al., 2009) is intriguing and warrants 
further scrutiny. 
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Fig. 7. NBPF1, Cby and CLU form a tri-molecular complex. 
An overview of the mutual interactions between NBPF1, Cby and CLU. The coiled-coil 
region in the N-terminus of NBPF1 interacts with the coiled-coil region in the cytoplasmic 
domain of Cby. The C-terminus of CLU interacts with the full-length Cby protein, as 
interactions with both the N-terminus and C-terminus are observed. It is uncertain whether 
CLU and NBPF1 interact directly (boxed question mark) (Modified after Vandepoele et al., 
2010, Elsevier (2010), reproduced by permission). 
6. Conclusion 
In this chapter we summarise the growing evidence for the recent emergence of the NBPF 
gene family and for its role in human evolution. The NBPF/DUF1220 domains in particular 
seem to have been important in this context. This evidence is based on the large increase in 
copy number of the NBPF/DUF1220 domain in humans. On the other hand, NBPF genes 
seem to be involved in cancer and in brain and developmental disorders due to their 
location in unstable high-identity duplication blocks, which leads to recurrent chromosomal 
rearrangements. One case of particular interest is neuroblastoma. Evidence for the 
involvement of NBPF genes in this type of cancer comes not only from disruption of NBPF1 
in a neuroblastoma patient, but also from gene expression studies and the association with 
neuroblastoma of a copy number variation of an NBPF paralog. Additionally, the regulatory 
elements and the identification of NBPF-interacting proteins indicate that the NBPF gene 
family plays a role in neuroblastoma. Involvement of NBPF genes in neuroblastoma and 
possibly as well in other cancers points to the value of studying this gene family further. 
Every step in the functional understanding of these genes could bring us closer to 
unravelling the molecular mechanisms underlying neuroblastoma development and could 
help us to develop more effective therapy. Such studies could also shed light on the impact 
these novel genes had on recent primate evolution. 
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